STOCK TITAN

Zoetis Inc - ZTS STOCK NEWS

Welcome to our dedicated page for Zoetis news (Ticker: ZTS), a resource for investors and traders seeking the latest updates and insights on Zoetis stock.

Zoetis Inc. (ZTS) drives innovation in animal health as the global leader in veterinary pharmaceuticals and diagnostics. This news hub provides investors and industry professionals with essential updates on developments impacting companion animal care and livestock health systems.

Access curated press releases and analysis covering product approvals, research breakthroughs, and financial performance. Our repository includes updates on vaccine innovations, parasiticides, diagnostic tools, and strategic partnerships across 100+ markets. Monitor earnings announcements, manufacturing expansions, and regulatory milestones that shape this $80B sector.

Bookmark this page for streamlined tracking of Zoetis' operational progress in developing solutions for pets and farm animals. Return regularly to stay informed about initiatives affecting animal welfare standards and agricultural productivity worldwide.

Rhea-AI Summary

Zoetis Inc. (NYSE: ZTS) has successfully completed the acquisition of Jurox, an Australian animal health company. This acquisition enhances Zoetis' product range, particularly with the addition of Alfaxan®, a leading anaesthetic for companion animals. The move is anticipated to provide greater global expansion opportunities and valuable insights into the Australian animal health market. Jurox's established operations, which include over 150 veterinary medicines, will contribute to Zoetis' growth in its fourth largest market based on revenue.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.76%
Tags
-
Rhea-AI Summary

Zoetis Inc. (NYSE:ZTS) will host a conference call on Nov. 3, 2022, at 8:30 a.m. ET, to discuss its third quarter 2022 financial results. CEO Kristin Peck and CFO Wetteny Joseph will lead the discussion and answer questions from analysts. The public can access the live webcast through the Zoetis investor website. The company reported $7.8 billion in revenue for 2021 and operates in over 100 countries, showcasing its strong global presence in animal health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.86%
Tags
conferences earnings
-
Rhea-AI Summary

For the ninth consecutive year, Zoetis has been recognized by Seramount as one of their 100 Best Companies, highlighting its commitment to family-friendly benefits and workplace flexibility. Additionally, A.J. Edge and Daniel Edge were honored as Working Parents of the Year. The company offers programs such as paid parental leave, childcare reimbursement, and mental health benefits to support its employees. These accolades emphasize Zoetis' dedication to inclusivity and employee well-being in its workplace culture.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
none
Rhea-AI Summary

Zoetis (NYSE: ZTS) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 2:05 p.m. ET. Wetteny Joseph, the Chief Financial Officer, will represent the company and answer analyst questions. A live audio webcast will be available at investor.zoetis.com, with a replay following the event. Zoetis, a leader in animal health, generated $7.8 billion in revenue in 2021 and operates in over 100 countries.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.67%
Tags
conferences
-
Rhea-AI Summary

Zoetis reported second-quarter 2022 revenue of $2.1 billion, a 5% increase year-over-year. Net income reached $529 million, equating to $1.12 per diluted share, marking a 3% rise. Operationally, revenue grew 8% and adjusted net income rose 9%, excluding foreign currency impacts. The company updated its 2022 guidance, projecting revenue between $8.225 billion and $8.325 billion and diluted EPS of $4.65 to $4.75 on a reported basis.

Despite growth, Zoetis faces challenges including foreign exchange fluctuations and commodity competition.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.25%
Tags
none
-
Rhea-AI Summary

Zoetis Inc (NYSE: ZTS) appointed Vanessa Broadhurst, Executive VP at Johnson & Johnson, to its Board of Directors, expanding the board from 11 to 12 members. Broadhurst brings extensive experience in consumer insights and direct-to-consumer marketing, set to enhance Zoetis' focus on pet owners. CEO Kristin Peck praised her strategic leadership and consumer healthcare expertise. Broadhurst is recognized as one of the "2022 Most Influential Black Executives in Corporate America" and will also serve on the Quality and Innovation Committee.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
management
Rhea-AI Summary

Zoetis Inc (NYSE:ZTS) is scheduled to host a webcast and conference call on August 4, 2022, at 8:30 a.m. ET. CEO Kristin Peck and CFO Wetteny Joseph will discuss the second quarter 2022 financial results. The public can access the live webcast via Zoetis' investor website, with a replay available post-event. Zoetis, a leader in animal health, reported $7.8 billion in revenue for 2021 and employs approximately 12,100 individuals globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.17%
Tags
conferences earnings
-
Rhea-AI Summary

Zoetis (NYSE:ZTS) has completed the acquisition of Basepaws, a petcare genetics company specializing in genetic testing and health risk assessments for pets. This strategic move enhances Zoetis' precision animal health portfolio, allowing for better disease detection and management for pet owners and veterinarians. Financial details of the acquisition were not disclosed. Zoetis aims to leverage Basepaws' insights for future innovations in petcare, supporting their commitment to advancing animal health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
-
Rhea-AI Summary

Zoetis (NYSE:ZTS), the global leader in animal health, announced participation in the Goldman Sachs 43rd Annual Global Healthcare Conference on June 13, 2022. Wetteny Joseph, CFO, will present at 4:20 p.m. ET. Investors can access a live audio webcast at investor.zoetis.com/events-presentations. A replay will be available post-event. In 2021, Zoetis generated revenue of $7.8 billion, employing approximately 12,100 staff worldwide, showcasing its commitment to advancing animal care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.43%
Tags
none
Zoetis Inc

NYSE:ZTS

ZTS Rankings

ZTS Stock Data

66.32B
445.07M
0.21%
95.67%
1.45%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
PARSIPPANY